Search clinical trials for: NLRC4 (SCAN4)

Total 5 results

Novartis Pharmaceuticals

Recruiting

Study to Evaluate the Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Autoinflammatory Diseases, Including NLRC4-GOF, XIAP Deficiency, or CDC42 Mutations (MASter-1)

NLRC4-GOF, AIFEC (Autoinflammation With Infantile Enterocolitis), XIAP Deficiency, CDC42 Mutations

Spain, France, United States, Canada, Japan, United Kingdom, Turkey, Czechia, Italy
Saglik Bilimleri Universitesi

Not yet recruiting

(NOD)-Like Receptors CARD Domain-Containing 4 Levels in Individuals With Periodontitis

Healthy | Periodontitis | Gingivitis

Turkey
AB2 Bio Ltd.

Completed

Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency

NLRC4-MAS | XIAP Deficiency

United States, Canada, Germany
AB2 Bio Ltd.

Active, not recruiting

Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency as Open Label Extension

NLRC4-MAS | XIAP Deficiency

United States, Canada, Germany
National Institute of Allergy and Infectious Diseases...

Recruiting

Natural History, Pathogenesis, and Outcome of Autoinflammatory Diseases (NOMID/CAPS, DIRA, CANDLE, SAVI, NLRC4-MAS, Still'S-like Diseases, and Other Undifferentiated Autoinflammatory Diseases)

DIRA | NLRC4-MAS | NOMID | SAVI | CANDLE

United States

3

Subscribe